The PARP inhibitor olaparib (AZD2281) as potent radiosensitizer of head and neck cancer cells

被引：0
|
作者：
Tinhofer, I [1 ]
Boyko-Fabian, M. [1 ]
Niehr, F. [1 ]
Keilholz, U. [2 ]
Budach, V [1 ]
机构：
[1] Charite Klin Radioonkol & Strahlentherapie, Berlin, Germany
[2] Charite Klin Hamatol & Onkol, Berlin, Germany
来源：
ONKOLOGIE | 2012年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：194 / 195
页数：2
相关论文
共 50 条
  • [1] The PARP inhibitor olaparib (AZD2281) as potent radiosensitizer of head and neck cancer cells
    Tinhofer, Inge
    Boyko-Fabian, Mariya
    Niehr, Franziska
    Keilholz, Ulrich
    Budach, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] The PARP inhibitor Olaparib (AZD2281) as an effective radiosensitizing Substance in Head and Neck Cancer Cells
    Tinhofer, I
    Niehr, F.
    Boyko-Fabian, M.
    Budach, V
    STRAHLENTHERAPIE UND ONKOLOGIE, 2013, 189 : 122 - 122
  • [3] Human biotransformation of olaparib (AZD2281) an oral poly(ADP-ribose) polymerase (PARP) inhibitor
    Clarkson-Jones, J.
    Page, C.
    Sarda, S.
    Swaisland, H.
    EJC SUPPLEMENTS, 2010, 8 (07): : 132 - 132
  • [4] Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer
    Audeh, M. W.
    Penson, R. T.
    Friedlander, M.
    Powell, B.
    Bell-McGuinn, K. M.
    Scott, C.
    Weitzel, J. N.
    Carmichael, J.
    Tutt, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] Sequence specific effects on DNA and cell damage with the PARP inhibitor olaparib (AZD2281) and carboplatin.
    Hays, J. L.
    Kim, G.
    Mariani, J.
    Murphy, R. F.
    Angelos, M.
    McCollum, A.
    Lu, J.
    Widemann, B. C.
    Lee, J.
    Kohn, E. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells
    Arun, Banu
    Akar, Ugur
    Gutierrez-Barrera, Angelica M.
    Hortobagyi, Gabriel N.
    Ozpolat, Bulent
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2015, 47 (01) : 262 - 268
  • [7] Mismatch repair proficiency as a predictor of response to the PARP inhibitor AZD2281
    Redman, R. A.
    York, S. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] Inhibition of PARP-1 by Olaparib (AZD2281) Increases the Radiosensitivity of a Lung Tumor Xenograft
    Senra, Joana M.
    Telfer, Brian A.
    Cherry, Kim E.
    McCrudden, Cian M.
    Hirst, David G.
    O'Connor, Mark J.
    Wedge, Stephen R.
    Stratford, Ian J.
    MOLECULAR CANCER THERAPEUTICS, 2011, 10 (10) : 1949 - 1958
  • [9] Olaparib (AZD2281; PARP inhibitor) and AZD7762 (CHK inhibitor) act synergistically to enhance cell death and reduce tumor growth in preclinical models
    Zabludoff, Sonya
    Cao, Zhu
    Hylander-Gans, Linda
    McCoon, Patricia
    Morosini, Deborah
    O'Connor, Mark
    Pablo, Lourdes
    Sheehy, Adam
    CANCER RESEARCH, 2009, 69
  • [10] A phase I trial of the PARP inhibitor olaparib (AZD2281) in combination with the antiangiogenic cediranib (AZD2171) in recurrent ovarian or triple-negative breast cancer
    Liu, J.
    Fleming, G. F.
    Tolaney, S. M.
    Birrer, M. J.
    Penson, R. T.
    Berlin, S. T.
    Whalen, C.
    Tyburski, K.
    Matijevich, K.
    Kasparian, E.
    Roche, M.
    Lee, H.
    Winer, E. P.
    Ivy, S. P.
    Matulonis, U.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345